Plain-English translation of NCT07033819 on ClinicalTrials.gov β Β· Source last updated Β· Translation generated Β· How we translate trials
Read our Ovarian Cancer research guide βPhase 2 β Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a combination of two medications β fuzuloparib and apatinib β given before surgery to patients with advanced ovarian cancer. You would receive this medication combination for 8 weeks (two 4-week cycles), and then doctors would reassess whether surgery is now possible. This approach is called 'neoadjuvant treatment,' meaning the medication comes before the main surgical treatment.
Some patients with advanced ovarian cancer have tumors that are too extensive or risky to remove surgically when first diagnosed. This trial is testing whether giving medication first can shrink the cancer enough to make surgery safer and more successful.
You likely qualify ifβ¦
You likely don't qualify ifβ¦
You would visit the clinic to receive the two medications over two 4-week cycles (8 weeks total). During this time, you would have blood tests and imaging scans (CT or MRI) to monitor how well the treatment is working. After 8 weeks, doctors will use imaging and other assessments to see if the cancer has shrunk enough to make surgery possible. If the treatment works well, you would then proceed to have surgery to remove the remaining cancer.
AI-generated summary from trial data Β· Jun 9, 2026 Β· Not medical advice
China